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Abstract 
Lipid vesicles in the nano range with ionic and nonionic surfactants are known as transfersomes.  The presence of 
surfactant in the bilayer structure makes the vesicles very flexible in nature and helps them to permeate through the 
stratum corneum. The purpose of this research was to develop and characterize a transfersomal formulation of raloxifene 
HCl to deliver it into systemic circulation through the transdermal route. The transfersomal formulation was prepared by 
the rotary evaporation method with phospholipon 90G and sorbitan 80. The particle size, zeta potential and 
polydispersity index (PDI) of the formulation were measured. The drug entrapment efficiency (EE%) of the vesicles was 
determined by an indirect ultracentrifugation method. Differential scanning calorimetry (DSC), ex-vivo skin permeation 
study, field emission scanning electron microscope (FESEM), high resolution transmission electron microscope (HRTEM) 
and confocal laser scanning microscopy (CLSM) study were carried out as parts of advanced characterization of the 
developed formulation. The vesicles were found to have an average particle size of 95.1±1.05nm with a PDI value of 
0.162±0.01 and zeta potential of +17.62±0.29 mV. EE% was recorded up to 90.9±1.15. Transdermal flux (J = 4.66±0.79 
μg/cm2hr) of the developed formulation showed a favorable value required for the formulation efficacy. FESEM and TEM 
study results proved the spherical and round structures of the vesicles. DSC showed that the raloxifene was in the non-
crystal form and was enclosed in the lipid bilayer. CLSM study proved the distribution of the drug in the stratum 
corneum, viable epidermis and dermis with high fluorescence intensity. The developed nano transfersomes of raloxifene 
HCl with sorbitan 80 showed encouraging results and can be further investigated for in vivo efficacy.   
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Introduction 
     Raloxifene HCl (Figure 1) is widely used in hormone 
replacement therapy (HRT) for the post-menopausal 
women, as it plays an important role in reducing the risk 
of breast cancer while acting on estrogenic receptors of 
bone and liver [1]. It belongs to selective estrogen 
receptor modulator (SERM) class. It comes under class II 
of BCS. It belongs to benzothiophene class and its 
molecular mass is 510.05.  It is selected as a potential 
alternative to HRT in postmenopausal patients and for 
treatment of osteoporosis and heart related disease while 
controlling the growth rate of breast cancer [2,3]. The 
pharmacokinetic pathway of raloxifene encounters a 
hostile environment of the gastrointestinal tract and 
hepatic metabolism, due to which the bioavailability of 
this compound is reduced to 2% only [4,5]. In modern day 
drug therapy, much more attention is paid to patient 
compliance while minimizing the intake of extra dose, 
reducing side effects and maximizing the therapeutic 
effect. The side effects associated with long term HRT are 
breast pain, uterine bleeding and chances of breast cancer 
[6]. The daily dosing of raloxifene HCl is 60mg to achieve 
its therapeutic plasma concentration. With the concern of 
reducing its side effects and to improve its bioavailability, 
a transfersomal system of raloxifene HCl was developed 
with sorbitan 80 as an edge activator. Transdermal drug 
delivery (TDD) system was selected as the delivery mode 
as this system has achieved huge attention in this aspect. 
Elastic liposome or transfersome as a novel transdermal 
drug delivery carrier has been reported to deliver drugs 
into systemic circulation while maintaining the patient 
compliance. Transfersomes consists of phospholipids 
(vesicle forming component) and a surfactant as an edge 
activator (EA) to impart flexibility and ultra-deformability 
within the vesicular structures [7]. In this work, we 
prepared transfersomes from phospholipid 90G and 
sorbitan 80 as an edge activator. Sorbitan-80, 
commercially also known as span-80, is a non-ionic 
surfactant with non-toxic profile and widely used in 
pharmaceutical industries.  It has also transdermal 
potential to deliver the active pharmaceutical ingredients.  
 
     There are various concepts behind the selection of non-
ionic surfactants for the drug delivery, especially for 
transdermal applications. The hydrophilic-lipophilic 
balance of span 80 is between 4-8 which is compatible for 
the formation of the vesicles as reported by Uchegbu and 
group [8]. Lipid vesicles with non-ionic surfactants were 
firstly reported in cosmetic industries in the seventies [9]. 
Their use in drug delivery was studied over the time by 
many authors,  drug targeting in the liver and spleen also  
 
have been reported for anticancer therapy [10].  
 
 
 
Figure 1: Molecular structure of raloxifene HCl. 
 
Materials  
     Phospholipon 90G was purchased from Lipoid, 
Ludwigshafen GMBH, Germany. Raloxifene HCl was 
purchased from Binzhou Neophar Pharmaceutical Co. 
Ltd., China. Sorbitan 80 was purchased from Merck 
(Germany). All other reagents used in this study were of 
analytical grade. Ultrapure distilled water was used 
throughout the experiment.  
 
Methods 
Preparation of Non-Ionic Transfersomes 
     The transfersomal formulation (TS-80) was prepared 
by rotary evaporation method [11]. Briefly PC90G, 
sorbitan 80 (85:15 w/w ratio of PC90G and sorbitan 80) 
and raloxifene HCl were taken in a round bottom flask 
and dissolved in 2:1 (v/v) ratio of chloroform and 
methanol. The solution was subjected to a rotary 
evaporation at 40-44 0C (above the transition 
temperature of PC90G) at 60 RP under a reduced 
pressure. After the solvent evaporation, a thin film was 
formed, kept it overnight for drying, and then hydrated 
with water in an orbital shaker for one hour at 42 °C. The 
vesicles obtained were multilamellar in nature with large 
diameter; they were reduced in size by sonication (ULTRA 
sonic 28X, Yucaipa, CA, USA). The resulted vesicles were 
further reduced in size by subsequent passing through the 
nylon sandwich membrane filters of 0.45um and 0.22um. 
Similarly for confocal laser scanning microscopy study, 
0.005% of 6-coumarin dye was added at the time of 
mixing with all the excipients and prepared in the same 
way as transfersomes formulation was prepared. The 
prepared vesicles were subjected to further 
characterization. Conventional liposomes were prepared 
with the same amount of PC-90G and raloxifene for the 
comparison with TS-80 formulation.  
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Particle Size, Distribution and Zeta Potential 
     The prepared transfersomes (TS-80) formulation was 
then subjected to size with size distribution and zeta-
potential evaluation by DLS (Zetamaster ZEM 5002 and 
Zetasizer Nano-Z; Malvern Instruments, Malvern, UK). All 
the tests were performed in triplicates and reported in 
the form of (mean ± S.D). 
 
Vesicular Morphology and Size 
     The vesicle morphology was analyzed by FESEM (JSM-
7800F, JEOL). The vesicles were uniformly spread on the 
glass cover slip, air dried and the specimen was coated 
with platinum by 208HR High Resolution Sputter Coater 
and examined at 3.0-5.0 kV with a magnification ranging 
from 500x to 10,000x. To confirm the size of the vesicles, 
the TS-80 formulation was subjected to a high resolution 
transmission electron microscope (HRTEM) (Tecnai G2 
20, FEI). Few small drops of the prepared vesicles were 
placed on a copper film coated grid, with a diameter of 
3.05 mm and 400 mesh size (Ted Pella, PELCO® 400 
Mesh Grids). Phosphotungustic acid (PTA) was used for 
the staining, the concentration of PTA used was 1%, and 
pH was maintained at 7.1. After drying the specimen on 
the grid, it was viewed with 50,000x to 200,000x 
enlargements at an accelerating voltage of 200 kV 
respectively [12].  
 
Drug Entrapment Efficiency (EE%)  
     Entrapment efficiency is defined as the drug entrapped 
in the bilayer of the vesicles. This was performed   by an 
indirect method as described by Jain, et al. [11]. TS-80 
formulations were centrifuged at 22,000 RPM for 30 
minutes at 4 ͦC to separate the vesicles from the unloaded 
drug. After an appropriate dilution, the supernatant was 
analyzed by an HPLC method. All the measurement was 
performed in triplicate as reported in form of mean±SD.   
 
Ex vivo Permeation and Deposition Study 
     Ex vivo release and permeation of raloxifene from the 
TS-80 formulations were measured by locally fabricated 
Franz diffusion cell. It’s having a receptor volume of 11 ml 
and a permeation area of 1.50 cm2. Rat abdominal skin 
was used as a permeation barrier. The receptor chamber 
was filled with a mixture of PBS 7.4 and ethanol in 60:40 
(v/v) as a receptor medium maintained at 37 ± 10C and 
set at a stirring rate of 100 RPM. The skin samples used 
for permeation studies were carefully viewed to ensure 
for any irregularity or damage such as cervices or tiny 
shacks. On the day of the experiment, skin samples 
thawed at room temperature. Before starting the 
experiment skin samples were equilibrated for 30 min at 
0.9% NaCl solution. Skin was placed over the Franz cell in 
such a manner by placing stratum corneum facing to the 
donor compartment while dermis layer faced the receptor 
compartment. A transdermal dose containing 1.2 mg of 
raloxifene which is entrapped in vesicles was taken, 
which is also a required therapeutic dose (Td) for the 
permeation study was placed in the donor compartment. 
As the study starts samples of volume 0.2ml was sampled 
out from the sample port from the receptor 
compartments from the diffusion cell at different time 
points 2, 4, 6 hours and immediately replenished with the 
same amount of receptor medium.  After the experiment 
the skin was washed carefully and cut into small pieces, 
and deposited drug in the skin layer was taken out after 
the centrifugation [13]. 
 
Amorphous State of Raloxifene  
     To confirm the amorphous state of raloxifene in the 
lipid bilayer, differential scanning calorimetry (DSC) R-1 
system (Mettler Toledo, U.S.A) was used. Raloxifene crude 
sample and its formulation (TS-80 where the drug was 
entrapped) was scanned. The scanning was done up to 
300°c at 10°c scanning rate. A blank alumina crucible was 
taken as the reference [14]. 
 
Confocal Laser Scanning Microscopy (CLSM) 
Study 
     The vesicles were loaded with coumarin-6 dye and 
subjected to 8 hours ex vivo skin permeation study. The 
skin samples were removed, washed and viewed on the z-
axis for vesicular permeation in the dermis and epidermis 
of the skin. A conventional liposome and ethanolic 
solution of the drug were used in the above mentioned 
characterization studies for a comparative analysis. The 
treated area of the skin samples was cut vertically with 
sections b/w 8-12 μm thickness and confocal microscopy 
was utilized to scan optically and analyze the penetration 
of vesicles in different skin layer through Z-axis of a Leica 
TCS SPE Confocal Microscope (Germany) while using an 
argon (AR) beam using the green filter which showed 
emission at 502 nm and excitation at 488 nm. Relative 
fluorescence intensity and depth of penetration of the 
particles with coumarin-6 dye in the skin layers were 
detected and analyzed by CLSM with Leica (Advanced 
Fluorescence) LAS SF software [15]. 
 
Results and Discussion 
Preparation Method of Transfersomes 
     The thin layer film method was selected to formulate 
the transfersomes (TS-80) because this technique is easy 
and results in high entrapment efficiency as compared to 
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the other reported methods [16]. The formulation of 
interest had the composition of 350mg PC90G, 62mg 
sorbitan 80 and 15mg raloxifene HCl. This was finalized 
after conducting an optimization test with formulation 
compositions as independent variables and particle size, 
PDI, and transdermal flux (J) as response variables (data 
are not included here). The multilamellar vesicles 
obtained after the hydration were further reduced to 
unilamellar vesicles by probe sonication at controlled 
amplification and finally extruding through the sandwich 
membrane of 0.45 and 0.22 μm. Transfersomes known to 
have self-optimizing and flexible nature which penetrate 
the skin pore much smaller than the size of vesicles [17].  
 
Size, PDI and Charge 
The size, charge, and PDI of the transfersome vesicles (TS-
80) were found to be 95.1±1.04 nm, +17.26±0.29 mV, and 
0.162±0.01, respectively. These results were in good 
agreement with many reported literatures for 
transdermal drug delivery [13,18]. The size range with 
120nm is considered an optimized size of lipid vesicles 
required for effective transdermal delivery of many drugs 
[18]. The lower PDI value of the formulation shows the 
homogenous population of the particles, which also 
results in sufficient transdermal delivery. The zeta-
potential of the non-ionic surfactant was dominated by 
drug and phospholipid PC-90G which is neutral. The ionic 
charge with higher negative or positive value of zeta 
potential is considered as optimum for creating enough 
dispersion in the formulation which can keep them stable. 
The pH of the formulation was recorded around 5.65. Size 
and zeta-potential of the formulation are shown in (Figure 
2) and (Figure 3) respectively.  
 
 
Figure 2: Representative size graph of the TS-80 
formulation confirming nano size of the prepared lipid 
vesicles. 
 
 
 
 
Figure 3: Zeta-potential graph of TS-80 formulation 
showing positive zeta potential (below 50 mV) of the 
obtained lipid vesicles. 
 
 
Vesicle Morphology and Particle Size 
     Their morphological structure and size of TS-80 
formulation were further verified by FESEM (Figure 4) 
and HRTEM (Figure 5), respectively. The size of the 
vesicles was in the nano range with a narrow PDI 
(0.162±0.01) due to the presence of edge activator and 
the technique used for their preparation [19]. The shape 
was found to be spherical as shown by FESEM. HRTEM 
shows the unilamellar structure and size with the actual 
diameter. 
 
 
 
Figure 4: FESEM images of raloxifene HCl loaded 
transfersomes (TS-80) composed of PC90G and sorbitan 
80. Magnification: 1300 times. 
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Figure 5: TEM photomicrograph of raloxifene HCl loaded 
transfersomes (TS-80) composed of PC90G and sorbitan 
80. Magnification: 46000 times. 
 
Entrapment Efficiency 
     The average entrapment efficiency 0f TS-80 
formulation was found to be 90.9±1.13%, which is 
optimum for effective drug permeation through the skin. 
The higher the entrapment the more chance of drug can 
be delivered through the skin [20]. 
 
Ex vivo Drug Permeation Study 
     The transdermal flux (J) of TS-80 formulation was 
4.66±0.79 μg/cm2hour which was more as compared to 
the conventional liposomes (1.0±0.3 μg/cm2.hour). This 
enhanced permeation of transfersomes vesicles through 
the skin pores, much smaller than their own diameter, 
was due to their flexibility and ability to retain their 
integrity while, they undergo a dramatic change in shape 
compared to the conventional liposomes [7, 21]. 
 
DSC Measurements  
     The melting point of raloxifene was found to be 
271.32°C, the peak of raloxifene was broadened when TS-
80 formulation was freeze dried and scanned as shown in 
(Figure 6). The amorphous state of the raloxifene was 
maintained even in the freeze dried form which confirms 
that raloxifene is entrapped within the lipid bilayer and 
remains in soluble state [22].  
 
 
Figure 6: DSC thermo gram of raloxifene (A) and TS-80 
(B). 
 
Confocal Laser Scanning Microscopy (CLSM) 
     The penetration ability of the formulation (TS-80) 
tagged with coumarin-6 dye, showed that the vesicles 
were evenly distributed throughout the stratum corneum, 
viable epidermis and dermis with high fluorescence 
intensity (Figure 7). CLSM studies depicted an increase in 
both the depth of penetration and amount of fluorescence 
intensity as compared to the conventional liposomes 
(Figure 7B) and ethanolic solution (Figure 7C).  
 
Figure 7: Confocal laser scanning micrographs of 6-coumarin-tagged transfersome vesicles (A), liposomes (B), and 
ethanolic PBS of raloxifene HCl (C). All the formulations were subjected to 8 hours of ex-vivo skin permeation study. 
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Conclusion 
     The rotary evaporation method utilized for the 
preparation of drug loaded transfersomes was found to 
provide the lipid vesicles with the desired range of 
particle size, PDI, zeta potential and ex vivo flux (J) for 
essential transdermal permeation and stability of the 
formulation. Advanced characterization of the developed 
formulation with DSC, SEM, HRTEM, CLSM confirmed 
transfersome vesicles with desired properties in 
agreement with the reported results for their transdermal 
efficacy [13, 23]. With these interesting in vitro results, 
the developed transfersomal formulation of raloxifene 
HCl with sorbitan 80 might be promising carriers for 
transdermal applications. 
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